Paper · 40001320
A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment.
Huang Z and 5 others. Thorac Cancer, 2025. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment. Papers, record 40001320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40001320
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Tumor Microenvironment | Major topic |
| Lung Neoplasms | Major topic |
| Fibroblast Growth Factors | Major topic |
| Receptors, Fibroblast Growth Factor | Major topic |
| Humans | |
| Prognosis | |
| Female | |
| Male | |
| Signal Transduction | |
| Middle Aged | |
| Aged |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Y-Young2024-0371 | Beijing Xisike Clinical Oncology Research Foundation | PubMed | ||
| 2021YFF1201001 | National Key Research and Development Program of China Stem Cell and Translational Research | PubMed | ||
| 23XHYD-12 | Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology Committee | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,174,843 | Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. | Trends Cancer | 2019 | https://conductscience.org/library/papers/31174843 | PubMed |
| 2 | 29,183,778 | Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. | Semin Cancer Biol | 2018 | https://conductscience.org/library/papers/29183778 | PubMed |
| 3 | 33,475,078 | Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma. | Anticancer Agents Med Chem | 2021 | https://conductscience.org/library/papers/33475078 | PubMed |
| 4 | 27,780,786 | The Eighth Edition Lung Cancer Stage Classification. | Chest | 2017 | https://conductscience.org/library/papers/27780786 | PubMed |
| 5 | 38,230,766 | Cancer statistics, 2024. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38230766 | PubMed |
| 6 | 39,543,657 | Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39543657 | PubMed |
| 7 | 36,235,266 | Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor. | Molecules | 2022 | https://conductscience.org/library/papers/36235266 | PubMed |
| 8 | 28,416,604 | Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. | Mol Cancer Ther | 2017 | https://conductscience.org/library/papers/28416604 | PubMed |
| 9 | 36,900,367 | Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology? | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36900367 | PubMed |
| 10 | 30,930,931 | FGF Signaling in Lung Development and Disease: Human Versus Mouse. | Front Genet | 2019 | https://conductscience.org/library/papers/30930931 | PubMed |
1 to 10 of 41
See all 41 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,621,139 | The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives. | iScience | 2026 | https://conductscience.org/library/papers/42621139 | PubMed |
| 41,133,008 | TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/41133008 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40001320
GET https://conductscience.org/api/papers/v1/40001320/references?page=2